Skip to main content
    M

    MaxCyte Inc (MXCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.18
    -0.01 (-0.84%)

    Market Cap: $122.87M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MaxCyte Inc (MXCT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    MaxCyte reported revenue of $33.03M for the fiscal year ended Dec 31, 2025, down 14.5% from the year before. That year, net income was -$44.63M with a net margin of -135.1%, operating cash flow was -$34.41M and free cash flow was -$36.18M. The quarter ended Sep 30, 2026 had revenue of $10.15M and net income of -$4.76M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $12.27M, a compound annual rate of 11.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$33.03M-14.5%81.2%-157.1%-135.1%
    Dec 2024$38.63M-6.4%81.6%-132.5%-106.3%
    Dec 2023$41.29M-6.7%88.5%-117.0%-91.8%
    Dec 2022$44.26M+30.6%88.5%-61.8%-53.3%
    Dec 2021$33.89M+29.5%89.2%-53.7%-56.3%
    Dec 2020$26.17M+21.0%89.4%-42.3%-45.2%
    Dec 2019$21.62M+29.7%88.4%-57.4%-59.6%
    Dec 2018$16.67M+19.2%89.0%-50.5%-53.2%
    Dec 2017$13.98M+14.0%89.6%-66.4%-70.9%
    Dec 2016$12.27MN/A89.3%-22.2%-27.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$33.03M$38.63M$41.29M$44.26M$33.89M$26.17M$21.62M$16.67M$13.98M$12.27M
    Cost of revenue$6.22M$7.10M$4.74M$5.10M$3.65M$2.77M$2.50M$1.84M$1.45M$1.31M
    Gross profit$26.80M$31.53M$36.55M$39.16M$30.25M$23.40M$19.12M$14.83M$12.53M$10.96M
    Research and development$20.82M$22.23M$23.82M$19.51M$15.41M$17.73M$17.59M$11.24M$11.28M$4.70M
    Operating income-$51.90M-$51.20M-$48.30M-$27.36M-$18.19M-$11.06M-$12.42M-$8.42M-$9.29M-$2.72M
    Net income-$44.63M-$41.05M-$37.92M-$23.57M-$19.08M-$11.82M-$12.89M-$8.87M-$9.92M-$3.35M
    EBITDA-$49.40MN/AN/A-$27.33M-$16.84M-$10.01M-$11.84M-$7.91M-$9.15M-$2.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.15M$7.27M$9.65M$7.30M$6.83M$8.51M$10.39M$8.69M$8.16M$10.43M$11.34M$15.66M
    Gross profit$8.47M$5.60M$8.08M$5.69M$5.23M$6.99M$8.89M$6.41M$6.24M$8.94M$9.94M$14.09M
    Operating income-$6.04M-$10.23M-$6.18M-$11.23M-$14.15M-$14.23M-$12.29M-$12.90M-$14.05M-$11.97M-$12.28M-$8.10M
    Net income-$4.76M-$8.87M-$4.75M-$9.60M-$12.42M-$12.36M-$10.26M-$10.60M-$11.56M-$9.38M-$9.53M-$5.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.46M by $18.61M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$202.51M$239.47M$268.27M$286.65M$284.12M$51.78M$29.99M$24.27M$31.40M$16.07M
    Current assets$118.37M$171.68M$190.19M$252.27M$270.43M$45.25M$24.45M$22.45M$30.55M$15.79M
    Cash and equivalents$20.07M$27.88M$46.51M$11.06M$47.78M$18.76M$15.21M$11.25M$25.34M$11.73M
    Total liabilities$31.02M$33.22M$36.11M$32.69M$21.22M$18.55M$16.38M$11.99M$11.80M$10.99M
    Short-term debt$1.46M$864.00K$774.00K$157.00K$527.20K$672.60K$508.90K$2.45M$854.10K$14.40K
    Long-term debtN/AN/AN/AN/AN/A$4.92M$4.90M$5.06M$4.18MN/A
    Shareholder equity$171.49M$206.25M$232.17M$253.97M$262.90M$33.23M$13.60M$12.28M$19.60M$5.08M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$182.48M$184.67M$194.47M$202.51M$213.48M$219.75M$229.96M$239.47M$248.61M$251.50M$257.93M$268.27M
    Total liabilities$31.55M$25.92M$26.59M$31.02M$33.20M$29.03M$30.55M$33.22M$35.31M$30.23M$31.57M$36.11M
    Cash and equivalents$13.37M$15.04M$14.56M$20.07M$12.97M$15.22M$23.39M$27.88M$36.96M$37.51M$22.25M$46.51M
    Shareholder equity$150.93M$158.75M$167.89M$171.49M$180.28M$190.72M$199.41M$206.25M$213.30M$221.26M$226.36M$232.17M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$34.41M-$27.61M-$21.69M-$14.78M-$10.68M-$8.78M-$8.80M-$10.49M-$9.68M-$2.33M
    Capital expenditures$1.77M$1.65M$3.70M$18.48M$3.83M$2.07M$1.27M$709.70K$609.70K$218.80K
    Free cash flow-$36.18M-$29.26M-$25.39M-$33.26M-$14.51M-$10.85M-$10.07M-$11.20M-$10.29M-$2.55M
    Investing cash flow$25.93M$6.93M$54.98M-$24.82M-$195.01M-$16.58M$454.50K-$3.83M-$609.70K-$218.80K
    Financing cash flow$656.00K$2.06M$2.14M$2.89M$234.72M$28.90M$12.31M$226.80K$23.90M$11.87M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.51M-$4.66M-$8.17M-$2.69M-$7.46M-$9.85M-$14.41M-$7.82M-$4.39M-$4.83M-$10.56M$981.00K
    Capital expenditures$59.00K$62.00K$72.00K$231.00K$300.00K$584.00K$653.00K$147.00K$406.00K$294.00K$804.00K$915.00K
    Free cash flow-$5.57M-$4.72M-$8.24M-$2.92M-$7.76M-$10.44M-$15.06M-$7.97M-$4.80M-$5.13M-$11.37M$66.00K
    Last 12 quarters

    Frequently Asked Questions About MXCT

    What is MaxCyte's annual revenue?

    MaxCyte reported revenue of $33.03M for the fiscal year ended Dec 31, 2025.

    How fast is MaxCyte's revenue growing?

    Revenue was down 14.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -9.3%.

    Is MaxCyte profitable?

    No. MaxCyte reported net income of -$44.63M for the fiscal year ended Dec 31, 2025, with a net margin of -135.1%.

    How much free cash flow does MXCT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$34.41M minus capital expenditures of $1.77M produced free cash flow of -$36.18M.

    How much debt does MaxCyte have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.46M and cash and equivalents of $20.07M.